it means a number of sub groups hit it out of the ball park but for the whole trial it looks like there was a treatment effect size of 50% reduction in 20% more of the experimental patients than controls. as the primary was 50% more this has not met but I just don’t think it’s going to matter a jot at the end of the day. They were always going to do another trial with grun in Europe anyway and too much of this data is landmark that won’t be able to be ignored by the fda.
Ann: Mesoblast Phase 3 Chronic Low Back Pain Results, page-101
-
- There are more pages in this discussion • 1,003 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.13 |
Change
0.035(3.21%) |
Mkt cap ! $1.284B | |||
| Open | High | Low | Value | Volume |
| $1.09 | $1.13 | $1.07 | $3.910M | 3.535M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 27197 | $1.11 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.13 | 43578 | 3 |
View Market Depth
| Last trade - 16.10pm 27/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |